The stock price of BridgeBio Pharma Inc (NASDAQ: BBIO) has plunged by -3.87 when compared to previous closing price of 28.43, but the company has seen a -6.50% decline in its stock price over the last five trading sessions. Reuters reported 2024-03-04 that BridgeBio Pharma has granted German drugmaker Bayer an exclusive license to commercialize its heart disease drug in Europe, the companies said on Monday.
Is It Worth Investing in BridgeBio Pharma Inc (NASDAQ: BBIO) Right Now?
Additionally, the 36-month beta value for BBIO is 1.04. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for BBIO is 138.81M and currently, short sellers hold a 10.29% ratio of that float. The average trading volume of BBIO on April 11, 2024 was 1.73M shares.
BBIO’s Market Performance
The stock of BridgeBio Pharma Inc (BBIO) has seen a -6.50% decrease in the past week, with a -5.56% drop in the past month, and a -31.21% fall in the past quarter. The volatility ratio for the week is 3.58%, and the volatility levels for the past 30 days are at 4.02% for BBIO. The simple moving average for the last 20 days is -5.29% for BBIO stock, with a simple moving average of -9.73% for the last 200 days.
Analysts’ Opinion of BBIO
Many brokerage firms have already submitted their reports for BBIO stocks, with Raymond James repeating the rating for BBIO by listing it as a “Outperform.” The predicted price for BBIO in the upcoming period, according to Raymond James is $45 based on the research report published on March 21, 2024 of the current year 2024.
BMO Capital Markets, on the other hand, stated in their research note that they expect to see BBIO reach a price target of $37. The rating they have provided for BBIO stocks is “Market Perform” according to the report published on January 31st, 2024.
Wells Fargo gave a rating of “Overweight” to BBIO, setting the target price at $58 in the report published on December 08th of the previous year.
BBIO Trading at -14.28% from the 50-Day Moving Average
After a stumble in the market that brought BBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.33% of loss for the given period.
Volatility was left at 4.02%, however, over the last 30 days, the volatility rate increased by 3.58%, as shares sank -4.77% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -27.77% lower at present.
During the last 5 trading sessions, BBIO fell by -6.50%, which changed the moving average for the period of 200-days by +74.52% in comparison to the 20-day moving average, which settled at $28.79. In addition, BridgeBio Pharma Inc saw -32.30% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BBIO starting from Scott Randal W., who sale 2,500 shares at the price of $34.00 back on Mar 01 ’24. After this action, Scott Randal W. now owns 6,500 shares of BridgeBio Pharma Inc, valued at $85,000 using the latest closing price.
Valantine Hannah, the Director of BridgeBio Pharma Inc, sale 2,915 shares at $37.75 during a trade that took place back on Feb 15 ’24, which means that Valantine Hannah is holding 1,764 shares at $110,041 based on the most recent closing price.
Stock Fundamentals for BBIO
Current profitability levels for the company are sitting at:
- -65.29 for the present operating margin
- 0.74 for the gross margin
The net margin for BridgeBio Pharma Inc stands at -73.08. The total capital return value is set at -1.51.
Based on BridgeBio Pharma Inc (BBIO), the company’s capital structure generated 4.51 points at debt to capital in total, while cash flow to debt ratio is standing at -0.3. The debt to equity ratio resting at -1.28. The interest coverage ratio of the stock is -14.93.
Currently, EBITDA for the company is -574.64 million with net debt to EBITDA at -2.35. When we switch over and look at the enterprise to sales, we see a ratio of 688.49. The receivables turnover for the company is 5.31for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.32.
Conclusion
In conclusion, BridgeBio Pharma Inc (BBIO) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
